Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
Paul ValensiDepartment of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, Bondy, FranceAbstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the pr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-06-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
| Online Access: | http://www.dovepress.com/biphasic-insulin-aspart-3070-biasp-30-in-the-treatment-of-type-1-and-t-a3229 |